Cargando…

Chromosome-specific retention of cancer-associated DNA hypermethylation following pharmacological inhibition of DNMT1

The DNA methylation status of the X-chromosome in cancer cells is often overlooked because of computational difficulties. Most of the CpG islands on the X-chromosome are mono-allelically methylated in normal female cells and only present as a single copy in male cells. We treated two colorectal canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Wiseman, Ashley K., Tiedemann, Rochelle L., Fan, Huihui, Shen, Hui, Madaj, Zachary, McCabe, Michael T., Pappalardi, Melissa B., Jones, Peter A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163065/
https://www.ncbi.nlm.nih.gov/pubmed/35654826
http://dx.doi.org/10.1038/s42003-022-03509-3
_version_ 1784719848521072640
author Wiseman, Ashley K.
Tiedemann, Rochelle L.
Fan, Huihui
Shen, Hui
Madaj, Zachary
McCabe, Michael T.
Pappalardi, Melissa B.
Jones, Peter A.
author_facet Wiseman, Ashley K.
Tiedemann, Rochelle L.
Fan, Huihui
Shen, Hui
Madaj, Zachary
McCabe, Michael T.
Pappalardi, Melissa B.
Jones, Peter A.
author_sort Wiseman, Ashley K.
collection PubMed
description The DNA methylation status of the X-chromosome in cancer cells is often overlooked because of computational difficulties. Most of the CpG islands on the X-chromosome are mono-allelically methylated in normal female cells and only present as a single copy in male cells. We treated two colorectal cancer cell lines from a male (HCT116) and a female (RKO) with increasing doses of a DNA methyltransferase 1 (DNMT1)-specific inhibitor (GSK3685032/GSK5032) over several months to remove as much non-essential CpG methylation as possible. Profiling of the remaining DNA methylome revealed an unexpected, enriched retention of DNA methylation on the X-chromosome. Strikingly, the identified retained X-chromosome DNA methylation patterns accurately predicted de novo DNA hypermethylation in colon cancer patient methylomes in the TCGA COAD/READ cohort. These results suggest that a re-examination of tumors for X-linked DNA methylation changes may enable greater understanding of the importance of epigenetic silencing of cancer related genes.
format Online
Article
Text
id pubmed-9163065
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-91630652022-06-05 Chromosome-specific retention of cancer-associated DNA hypermethylation following pharmacological inhibition of DNMT1 Wiseman, Ashley K. Tiedemann, Rochelle L. Fan, Huihui Shen, Hui Madaj, Zachary McCabe, Michael T. Pappalardi, Melissa B. Jones, Peter A. Commun Biol Article The DNA methylation status of the X-chromosome in cancer cells is often overlooked because of computational difficulties. Most of the CpG islands on the X-chromosome are mono-allelically methylated in normal female cells and only present as a single copy in male cells. We treated two colorectal cancer cell lines from a male (HCT116) and a female (RKO) with increasing doses of a DNA methyltransferase 1 (DNMT1)-specific inhibitor (GSK3685032/GSK5032) over several months to remove as much non-essential CpG methylation as possible. Profiling of the remaining DNA methylome revealed an unexpected, enriched retention of DNA methylation on the X-chromosome. Strikingly, the identified retained X-chromosome DNA methylation patterns accurately predicted de novo DNA hypermethylation in colon cancer patient methylomes in the TCGA COAD/READ cohort. These results suggest that a re-examination of tumors for X-linked DNA methylation changes may enable greater understanding of the importance of epigenetic silencing of cancer related genes. Nature Publishing Group UK 2022-06-02 /pmc/articles/PMC9163065/ /pubmed/35654826 http://dx.doi.org/10.1038/s42003-022-03509-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Wiseman, Ashley K.
Tiedemann, Rochelle L.
Fan, Huihui
Shen, Hui
Madaj, Zachary
McCabe, Michael T.
Pappalardi, Melissa B.
Jones, Peter A.
Chromosome-specific retention of cancer-associated DNA hypermethylation following pharmacological inhibition of DNMT1
title Chromosome-specific retention of cancer-associated DNA hypermethylation following pharmacological inhibition of DNMT1
title_full Chromosome-specific retention of cancer-associated DNA hypermethylation following pharmacological inhibition of DNMT1
title_fullStr Chromosome-specific retention of cancer-associated DNA hypermethylation following pharmacological inhibition of DNMT1
title_full_unstemmed Chromosome-specific retention of cancer-associated DNA hypermethylation following pharmacological inhibition of DNMT1
title_short Chromosome-specific retention of cancer-associated DNA hypermethylation following pharmacological inhibition of DNMT1
title_sort chromosome-specific retention of cancer-associated dna hypermethylation following pharmacological inhibition of dnmt1
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163065/
https://www.ncbi.nlm.nih.gov/pubmed/35654826
http://dx.doi.org/10.1038/s42003-022-03509-3
work_keys_str_mv AT wisemanashleyk chromosomespecificretentionofcancerassociateddnahypermethylationfollowingpharmacologicalinhibitionofdnmt1
AT tiedemannrochellel chromosomespecificretentionofcancerassociateddnahypermethylationfollowingpharmacologicalinhibitionofdnmt1
AT fanhuihui chromosomespecificretentionofcancerassociateddnahypermethylationfollowingpharmacologicalinhibitionofdnmt1
AT shenhui chromosomespecificretentionofcancerassociateddnahypermethylationfollowingpharmacologicalinhibitionofdnmt1
AT madajzachary chromosomespecificretentionofcancerassociateddnahypermethylationfollowingpharmacologicalinhibitionofdnmt1
AT mccabemichaelt chromosomespecificretentionofcancerassociateddnahypermethylationfollowingpharmacologicalinhibitionofdnmt1
AT pappalardimelissab chromosomespecificretentionofcancerassociateddnahypermethylationfollowingpharmacologicalinhibitionofdnmt1
AT jonespetera chromosomespecificretentionofcancerassociateddnahypermethylationfollowingpharmacologicalinhibitionofdnmt1